Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAN-DUCT / TRITICC-3 durvalumab plus intraductal radiofrequency ablation for cholangiocarcinoma
2023-509165-21-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) and intrahepatic cholangiocarcinoma (ICC), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Overall survival rate at 12 months. Planned start Aug 2024; status: authorised.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
cholangiocarcinoma (CCA)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2023-509165-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509165-21-00.